argenx

argenx is a global immunology company founded in 2008 that develops antibody-based solutions for severe autoimmune diseases. Its work centres on an antibody innovation ecosystem spanning immunology, antibody engineering and discovery, neonatal Fc receptor (FcRn) biology and autoimmune disease therapeutics. The company operates internationally across the biopharmaceuticals sector.

Its lead product, VYVGART (efgartigimod alfa), is a first-in-class neonatal Fc receptor blocker approved for the treatment of generalized myasthenia gravis. argenx states that the molecule has potential application across dozens of severe autoimmune conditions, extending its reach beyond the neurology indication for which it is currently approved.

The company's name draws on the myth of the Argonauts, chosen to emphasise the power of the team over individual heroes. Its stated cultural pillars are Innovation, Co-creation, Excellence, Humility and Empowerment, and a philosophy of co-creation shapes its business relationships and collaborations. Employees work in a culture of urgency, with pioneering scientists and antibody engineers working side by side, and a patient-centric purpose informed by the resilience and hope of patients.